Treating Transplant-Ineligible Patients With HCC and Liver-Confined Disease

Opinion
Video

Focusing on liver-directed therapy, the panel provides clinical insights on the treatment of patients with hepatocellular carcinoma who have liver-confined disease and are not candidates for transplant.

Recent Videos
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Related Content
Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma

Harrison Widelitz
September 26th 2024
Article

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver Cancer

Morgan Bayer
September 17th 2024
Article

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer

Harrison Widelitz
September 16th 2024
Article

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable Liver Cancer

Russ Conroy
August 21st 2024
Article

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

EMA Validates Application for Nivolumab/Ipilimumab in Liver Cancer Type

Roman Fabbricatore
July 22nd 2024
Article

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.